Careers  |  Sign In  |  Register

Latest Additions

[case_image][/case_image] [case_image_citation] Stephen Colden Cahill, DO, and Schield Wikas, DO - Series Editor [/case_image_citation] [signs_symptoms] At the end of summer, a 37-year-old woman presented for consultation about a 5-year history of a pruritic rash. The rash originally had started...
Elizabeth R. Plimack, MD, MS, chief of the Division of Genitourinary Medical Oncology, director of Genitourinary Clinical Research, and professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, explains outcomes seen in the recent phase 3 KEYNOTE-426 clinical trial for previously...
Bradley McGregor, MD, clinical director at Lank Center for Genitourinary Oncology, senior physician at Dana-Farber Cancer Institute, and instructor of medicine at Harvard Medical School, discusses a new clinical trial for patients with non-clear cell renal cell carcinoma (RCC) using a combination of...
Occupational therapists and occupational therapy (OT) assistants at NYU Langone Health are finding themselves working on the front line of this pandemic to help patients recover from COVID-19. Occupational therapy practitioners work with people of all ages to facilitate participation in everyday...
Daniel George, MD, questions whether debulking nephrectomy is still necessary in the age of targeted therapies. In a one-sided non-inferiority study, sunitinib alone was compared to nephrectomy. The data suggested that sunitinib alone was not inferior to nephrectomy, however, patients who receive...
A retrospective study, looking at nine years of genome hybridization arrays, compared the prognosis of melanoma patients carrying a partial deletion of chromosome 3 compared with patients whose uveal melanomas (UMs) lack such deletion. The data showed that patients with the partial deletion of chromosome...
Even before COVID-19 ravaged the medical workforce, physicians, nurses, and other health workers were at increased risk for burnout and depression. Although these professionals are equipped to manage the intensity of a medical crisis, they're not necessarily trained to deal with the mental health aftermath....
In an interview during the 2020 OncLive® State of the Science Summit™ on Advanced Melanoma, Tracey Liebman, MD, assistant professor in the Ronald O. Perelman Department of Dermatology at the NYU School of Medicine, NYU Langone Health, discussed the identification and management of treatment-related...
How would you diagnose this week's Derm Case Challenge?
Studies of pembrolizumab have shown promising antitumor activity across a wide cohort of patients with clear cell renal cell carcinoma (ccRCC). The results of a recent study, named KEYNOTE-427, showed a favorable safety profile, similar to that established in other trials focused on other tumor types. In...